The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the United States.
 
Neehar Parikh
Consulting or Advisory Role - Eisai
 
Laura Malahias
No Relationships to Disclose
 
Robert S Brown
Honoraria - Abbvie; Dova Pharmaceuticals; Gilead Sciences; Intercept Pharmaceuticals; Shionogi
Consulting or Advisory Role - Abbvie; Dova Pharmaceuticals; Gilead Sciences; Intercept Pharmaceuticals; Shionogi
Research Funding - Abbvie (Inst); Dova Pharmaceuticals (Inst); Gilead Sciences (Inst); Intercept Pharmaceuticals (Inst); Shionogi (Inst)
 
Roniel Cabrera
Consulting or Advisory Role - Target Pharmasolutions
Research Funding - Bayer (Inst); Eisai (Inst); Exelixis (Inst); Sillajen (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Sillajen
 
Patricia Denise Jones
Consulting or Advisory Role - Dova Pharmaceuticals
 
Charles Landis
Research Funding - Abbvie; Conatus; Gilead Sciences; Intercept Pharmaceuticals
 
Hannah Lee
No Relationships to Disclose
 
Parvez Mantry
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; BTG; Eisai; GENFIT; Gilead Sciences; Intercept Pharmaceuticals; Salix; Sirtex Medical; Tobira Therapeutics; Valeant Pharmaceuticals International
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; BTG; Eisai; GENFIT; Gilead Sciences; Intercept Pharmaceuticals; Salix; Sirtex Medical; Tobira Therapeutics; Valeant Pharmaceuticals International
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); BTG (Inst); GENFIT (Inst); Gilead Sciences (Inst); Intercept Pharmaceuticals (Inst); Salix (Inst); Sirtex Medical (Inst)
 
Edward Mena
Consulting or Advisory Role - Dova Pharmaceuticals
Speakers' Bureau - Abbvie; Gilead Sciences; Intercept Pharmaceuticals; Salix
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Intercept Pharmaceuticals; Salix
 
Nishant Poddar
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Ipsen
 
K. Rajender Reddy
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Dova Pharmaceuticals; Janssen; Merck; Shionogi
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Conatus (Inst); Intercept Pharmaceuticals (Inst); Mallinckrodt (Inst); Merck (Inst)
 
Roshan Shrestha
Honoraria - Abbvie; Boston Scientific; Dova Pharmaceuticals; Gilead Sciences; Intercept Pharmaceuticals; Salix
Consulting or Advisory Role - Abbvie; Boston Scientific; Dova Pharmaceuticals; Gilead Sciences; Intercept Pharmaceuticals; Salix
Speakers' Bureau - Abbvie; Boston Scientific; Dova Pharmaceuticals; Gilead Sciences; Intercept Pharmaceuticals; Salix
Research Funding - Intercept Pharmaceuticals (Inst); Ocera Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Boston Scientific; Dova Pharmaceuticals; Gilead Sciences; Intercept Pharmaceuticals; Salix
 
Paul Thuluvath
Honoraria - Abbvie; Gilead Sciences
Consulting or Advisory Role - Abbvie; Eisai; Gilead Sciences
Speakers' Bureau - Abbvie; Gilead Sciences
Research Funding - Abbvie (Inst); Allergan (Inst); Conatus (Inst); Cymabay Therapeutics (Inst); Eisai (Inst); Sillajen (Inst); Target Pharmasolutions (Inst); Tobira Therapeutics (Inst); Zydus Pharmaceuticals (Inst)
 
Richard Zink
Stock and Other Ownership Interests - Illumina
 
Amit G. Singal
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Eisai; Exact Sciences; Exelixis; Gilead Sciences; Glycotest; Roche
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Gilead Sciences
Research Funding - Abbvie